TOP ARTICLE THIS WEEK

“RNAi create opportunities that are difficult to achieve with conventional approaches” Paul Nioi (interview)

Paul Nioi, SVP of Research at Alnylam Pharmaceuticals, discusses the development of RNA interference (RNAi) medicines, twenty years after Fire and Mello’s Nobel Prize — from scientific discovery to an


This post is also available in: FR DE